Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May;5(3):112-34.
doi: 10.1177/2040622314523062.

Update on the therapy of Behçet disease

Zeinab Saleh  1 , Thurayya Arayssi  2
Affiliations
Review

Update on the therapy of Behçet disease

Zeinab Saleh et al. Ther Adv Chronic Dis. 2014 May.

Abstract

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

Keywords: Behçet disease; Behçet syndrome; biologic therapy; therapy; treatment; tumor necrosis factor α.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

References

    1. Abalos-Medina G., Sanchez-Cano D., Ruiz-Villaverde G., Ruiz-Villaverde R., Quirosa Flores S., Raya Alvarez E. (2009) Successful use of infliximab in a patient with neuro-Behcet’s disease. Int J Rheum Dis 12: 264–266 - PubMed
    1. Abu El-Asrar A., Abboud E., Aldibhi H., Al-Arfaj A. (2005) Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet’s disease. Int Ophthalmol 26: 83–92 - PubMed
    1. Accorinti M., Pirraglia M., Paroli M., Priori R., Conti F., Pivetti-Pezzi P. (2007) Infliximab treatment for ocular and extraocular manifestations of Behcet’s disease. Jap J Ophthalmol 51: 191–196 - PubMed
    1. Adan A., Hernandez V., Ortiz S., Molina J., Pelegrin L., Espinosa G., Sanmarti R. (2010) Effects of infliximab in the treatment of refractory posterior uveitis of Behcet’s disease after withdrawal of infusions. Int Ophthalmol 30: 577–581 - PubMed
    1. Adler S., Baumgartner I., Villiger P. M. (2012) Behcet’s disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res 64: 607–611 - PubMed

LinkOut - more resources